Musculoskeletal Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major musculoskeletal pain markets reached a value of US$ 3,975.7 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 5,399.8 Million by 2034, exhibiting a growth rate (CAGR) of 2.82% during 2024-2034.
The musculoskeletal pain market has been comprehensively analyzed in IMARC's new report titled "Musculoskeletal Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Musculoskeletal pain refers to discomfort or pain that affects the muscles, bones, ligaments, tendons, or other structures that support the body's movement. The pain associated with this ailment can be acute, lasting for a shorter amount of time, or chronic, extending for several weeks, months, or even years. The symptoms can vary in intensity based on the specific area of the body affected. Some common indications include a dull, aching sensation to sharp, intense pain, stiffness, swelling, muscle weakness, tenderness, limited range of motion, etc. Individuals suffering from this disease may also experience a sense of overall tiredness due to poor sleep quality. The diagnosis of musculoskeletal pain is based on a review of the patient's medical history, clinical features, and physical exam. The healthcare professional may also perform several diagnostic procedures, such as X-rays, ultrasounds, magnetic resonance imaging, etc., to obtain detailed images of the soft tissues that may indicate the causes of the underlying symptoms. In some cases, electromyography is recommended to measure the electrical activities of nerves and muscles in patients.
The rising cases of acute injuries, such as sprains and fractures, which can lead to localized pain in the affected muscles, ligaments, tendons, bones, etc., are primarily driving the musculoskeletal pain market. In addition to this, the increasing incidences of several associated risk factors, including obesity, genetic predisposition, sedentary lifestyle, excessive physical activity, muscular imbalance, poor posture, etc., are further augmenting the market growth. Moreover, the emerging popularity of effective medications, such as nonsteroidal anti-inflammatory drugs, muscle relaxants, pain relievers, etc., to relieve disease symptoms is also creating a positive outlook for the market. Apart from this, the widespread adoption of massage therapy, which helps to relax muscles, improve blood circulation, reduce muscle tension, and alleviate pain, is further bolstering the market growth. Additionally, the escalating utilization of cognitive-behavioral therapy to treat the condition, since it can identify and modify negative thought patterns and behaviors, is acting as another significant growth-inducing factor. Besides this, the rising demand for mindfulness-based stress reduction techniques that can promote relaxation and enhance overall well-being among patients is expected to drive the musculoskeletal pain market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the musculoskeletal pain market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for musculoskeletal pain and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the musculoskeletal pain market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the musculoskeletal pain market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the musculoskeletal pain market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current musculoskeletal pain marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the musculoskeletal pain market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the musculoskeletal pain market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the musculoskeletal pain market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of musculoskeletal pain across the seven major markets?
What is the number of prevalent cases (2018-2034) of musculoskeletal pain by age across the seven major markets?
What is the number of prevalent cases (2018-20343) of musculoskeletal pain by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with musculoskeletal pain across the seven major markets?
What is the size of the musculoskeletal pain patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of musculoskeletal pain?
What will be the growth rate of patients across the seven major markets?
Musculoskeletal Pain: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for musculoskeletal pain drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the musculoskeletal pain market?
What are the key regulatory events related to the musculoskeletal pain market?
What is the structure of clinical trial landscape by status related to the musculoskeletal pain market?
What is the structure of clinical trial landscape by phase related to the musculoskeletal pain market?
What is the structure of clinical trial landscape by route of administration related to the musculoskeletal pain market?
The musculoskeletal pain market has been comprehensively analyzed in IMARC's new report titled "Musculoskeletal Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Musculoskeletal pain refers to discomfort or pain that affects the muscles, bones, ligaments, tendons, or other structures that support the body's movement. The pain associated with this ailment can be acute, lasting for a shorter amount of time, or chronic, extending for several weeks, months, or even years. The symptoms can vary in intensity based on the specific area of the body affected. Some common indications include a dull, aching sensation to sharp, intense pain, stiffness, swelling, muscle weakness, tenderness, limited range of motion, etc. Individuals suffering from this disease may also experience a sense of overall tiredness due to poor sleep quality. The diagnosis of musculoskeletal pain is based on a review of the patient's medical history, clinical features, and physical exam. The healthcare professional may also perform several diagnostic procedures, such as X-rays, ultrasounds, magnetic resonance imaging, etc., to obtain detailed images of the soft tissues that may indicate the causes of the underlying symptoms. In some cases, electromyography is recommended to measure the electrical activities of nerves and muscles in patients.
The rising cases of acute injuries, such as sprains and fractures, which can lead to localized pain in the affected muscles, ligaments, tendons, bones, etc., are primarily driving the musculoskeletal pain market. In addition to this, the increasing incidences of several associated risk factors, including obesity, genetic predisposition, sedentary lifestyle, excessive physical activity, muscular imbalance, poor posture, etc., are further augmenting the market growth. Moreover, the emerging popularity of effective medications, such as nonsteroidal anti-inflammatory drugs, muscle relaxants, pain relievers, etc., to relieve disease symptoms is also creating a positive outlook for the market. Apart from this, the widespread adoption of massage therapy, which helps to relax muscles, improve blood circulation, reduce muscle tension, and alleviate pain, is further bolstering the market growth. Additionally, the escalating utilization of cognitive-behavioral therapy to treat the condition, since it can identify and modify negative thought patterns and behaviors, is acting as another significant growth-inducing factor. Besides this, the rising demand for mindfulness-based stress reduction techniques that can promote relaxation and enhance overall well-being among patients is expected to drive the musculoskeletal pain market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the musculoskeletal pain market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for musculoskeletal pain and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the musculoskeletal pain market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the musculoskeletal pain market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the musculoskeletal pain market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current musculoskeletal pain marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the musculoskeletal pain market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the musculoskeletal pain market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the musculoskeletal pain market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of musculoskeletal pain across the seven major markets?
What is the number of prevalent cases (2018-2034) of musculoskeletal pain by age across the seven major markets?
What is the number of prevalent cases (2018-20343) of musculoskeletal pain by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with musculoskeletal pain across the seven major markets?
What is the size of the musculoskeletal pain patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of musculoskeletal pain?
What will be the growth rate of patients across the seven major markets?
Musculoskeletal Pain: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for musculoskeletal pain drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the musculoskeletal pain market?
What are the key regulatory events related to the musculoskeletal pain market?
What is the structure of clinical trial landscape by status related to the musculoskeletal pain market?
What is the structure of clinical trial landscape by phase related to the musculoskeletal pain market?
What is the structure of clinical trial landscape by route of administration related to the musculoskeletal pain market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MUSCULOSKELETAL PAIN - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MUSCULOSKELETAL PAIN - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MUSCULOSKELETAL PAIN - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MUSCULOSKELETAL PAIN - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MUSCULOSKELETAL PAIN - UNMET NEEDS
10 MUSCULOSKELETAL PAIN - KEY ENDPOINTS OF TREATMENT
11 MUSCULOSKELETAL PAIN - MARKETED PRODUCTS
11.1 List of Musculoskeletal Pain Marketed Drugs Across the Top 7 Markets
11.1.1 Amrix (Cyclobenzaprine extended release) - Adare Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Cymbalta (Duloxetine) - Eli Lilly and Company
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 MUSCULOSKELETAL PAIN - PIPELINE DRUGS
12.1 List of Musculoskeletal Pain Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. MUSCULOSKELETAL PAIN - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MUSCULOSKELETAL PAIN – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MUSCULOSKELETAL PAIN - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Musculoskeletal Pain - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Musculoskeletal Pain - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Musculoskeletal Pain - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Musculoskeletal Pain - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Musculoskeletal Pain - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Musculoskeletal Pain - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Musculoskeletal Pain - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Musculoskeletal Pain - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Musculoskeletal Pain - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Musculoskeletal Pain - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Musculoskeletal Pain - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Musculoskeletal Pain - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Musculoskeletal Pain - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Musculoskeletal Pain - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Musculoskeletal Pain - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Musculoskeletal Pain - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Musculoskeletal Pain - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Musculoskeletal Pain - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Musculoskeletal Pain - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Musculoskeletal Pain - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Musculoskeletal Pain - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Musculoskeletal Pain - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Musculoskeletal Pain - Access and Reimbursement Overview
16 MUSCULOSKELETAL PAIN - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MUSCULOSKELETAL PAIN MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MUSCULOSKELETAL PAIN MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MUSCULOSKELETAL PAIN - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MUSCULOSKELETAL PAIN - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MUSCULOSKELETAL PAIN - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MUSCULOSKELETAL PAIN - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MUSCULOSKELETAL PAIN - UNMET NEEDS
10 MUSCULOSKELETAL PAIN - KEY ENDPOINTS OF TREATMENT
11 MUSCULOSKELETAL PAIN - MARKETED PRODUCTS
11.1 List of Musculoskeletal Pain Marketed Drugs Across the Top 7 Markets
11.1.1 Amrix (Cyclobenzaprine extended release) - Adare Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Cymbalta (Duloxetine) - Eli Lilly and Company
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 MUSCULOSKELETAL PAIN - PIPELINE DRUGS
12.1 List of Musculoskeletal Pain Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. MUSCULOSKELETAL PAIN - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MUSCULOSKELETAL PAIN – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MUSCULOSKELETAL PAIN - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Musculoskeletal Pain - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Musculoskeletal Pain - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Musculoskeletal Pain - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Musculoskeletal Pain - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Musculoskeletal Pain - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Musculoskeletal Pain - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Musculoskeletal Pain - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Musculoskeletal Pain - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Musculoskeletal Pain - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Musculoskeletal Pain - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Musculoskeletal Pain - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Musculoskeletal Pain - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Musculoskeletal Pain - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Musculoskeletal Pain - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Musculoskeletal Pain - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Musculoskeletal Pain - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Musculoskeletal Pain - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Musculoskeletal Pain - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Musculoskeletal Pain - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Musculoskeletal Pain - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Musculoskeletal Pain - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Musculoskeletal Pain - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Musculoskeletal Pain - Access and Reimbursement Overview
16 MUSCULOSKELETAL PAIN - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MUSCULOSKELETAL PAIN MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MUSCULOSKELETAL PAIN MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
